Secondary Logo

Institutional members access full text with Ovid®

Efficacy of direct oral anticoagulants on left ventricular thrombus

Turgay Yildirim, Özgea; Akşit, Ercanb; Aydin, Fatiha; Hüseyinoğlu Aydin, Ayşea

Blood Coagulation & Fibrinolysis: April 2019 - Volume 30 - Issue 3 - p 96–103
doi: 10.1097/MBC.0000000000000801

Left ventricular thrombus (LVT) is a commonly seen complication of myocardial infarction and it also can be seen because of hypertrophic cardiomyopathies, nonischemic dilated cardiomyopathies, malignancies, and so on. Guidelines suggest the use of warfarin for left ventricular thrombi, but recent case reports show that direct oral anticoagulants (DOACs) are beginning to be used for this complication. DOACs are strong alternatives for warfarin because of their efficacy and safety even though there is no randomized controlled trial that proves the effect of DOACs against LVT. In this article, we gather the case reports of DOACs against left ventricular thrombi in various conditions.

aDepartment of Cardiology, Eskisehir State Hospital, Eskisehir

bDepartment of Cardiology, Canakkale Onsekiz Mart University, Çanakkale, Turkey

Correspondence to Özge Turgay Yildirim, MD, Çamlica Mah, Güfte Sokak Natura Evleri A1 Blok Daire 3Tepebaşi/Eskişehir Tel: +905326876626; e-mail:

Received 17 October, 2018

Revised 21 January, 2019

Accepted 19 February, 2019

Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.